FLT3 and acute myeloid leukemia: We assessed the combined activity with ponatinib, a multikinase type 2-inhibitor [28], with crenolanib, a selective FLT3 type 1-inhibitor [29], and with PKC412 (midostaurin), a FLT3 inhibitor, which will become approved for treatment of FLT3ITD positive AML in the near future [30].